BRAF and colorectal carcinoma: Notably, the combination of lycorine plus vemurafenib (a BRAF inhibitor) in a CRC xenograft mouse model resulted in a dramatically enhanced anti-tumor effect without obvious side effects compared with the effects of monotherapy.